RT Journal Article
T1 Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.
A1 Ruiz-Antorán, Belén
A1 Sancho-López, Aránzazu
A1 Torres, Ferrán
A1 Moreno-Torres, Víctor
A1 de Pablo-López, Itziar
A1 García-López, Paulina
A1 Abad-Santos, Francisco
A1 Rosso-Fernández, Clara M
A1 Aldea-Perona, Ana
A1 Montané, Eva
A1 Aparicio-Hernández, Ruth M
A1 Llop-Rius, Roser
A1 Pedrós, Consuelo
A1 Gijón, Paloma
A1 Hernández-Carballo, Carolina
A1 Pedrosa-Martínez, María J
A1 Rodríguez-Jiménez, Consuelo
A1 Prada-Ramallal, Guillermo
A1 Cabrera-García, Lourdes
A1 Aguilar-García, Josefa A
A1 Sanjuan-Jimenez, Rocío
A1 Ortiz-Barraza, Evelyn I
A1 Sánchez-Chica, Enrique
A1 Fernández-Cruz, Ana
A1 TOCICOV-study group, 
K1 COVID-19
K1 Mortality
K1 SARS-CoV-2
K1 Steroids
K1 Tocilizumab
AB We aimed to determine the impact of tocilizumab use on severe COVID-19 (coronavirus disease 19) pneumonia mortality. We performed a multicentre retrospective cohort study in 18 tertiary hospitals in Spain from March to April 2020. Consecutive patients admitted with severe COVID-19 treated with tocilizumab were compared to patients not treated with tocilizumab, adjusting by inverse probability of the treatment weights (IPTW). Tocilizumab's effect in patients receiving steroids during the 48 h following inclusion was analysed. During the study period, 506 patients with severe COVID-19 fulfilled the inclusion criteria. Among them, 268 were treated with tocilizumab and 238 patients were not. Median time to tocilizumab treatment from onset of symptoms was 11 days [interquartile range (IQR) 8-14]. Global mortality was 23.7%. Mortality was lower in patients treated with tocilizumab than in controls: 16.8% versus 31.5%, hazard ratio (HR) 0.514 [95% confidence interval (95% CI) 0.355-0.744], p  These results show that survival of patients with severe COVID-19 is higher in those treated with tocilizumab than in those not treated and that tocilizumab's effect adds to that of steroids administered to non-intubated patients with COVID-19 during the first 48 h of presenting with respiratory failure despite oxygen therapy. Randomised controlled studies are needed to confirm these results. European Union electronic Register of Post-Authorization Studies (EU PAS Register) identifier, EUPAS34415.
SN 2193-8229
YR 2020
FD 2020-12-06
LK https://hdl.handle.net/10668/26780
UL https://hdl.handle.net/10668/26780
LA en
DS RISalud
RD Feb 23, 2025